Ophthalmic formulation of solid nanoparticles permits the retinal therapy, and lead to the therapy in the glaucoma patient
| Project/Area Number |
25860129
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | ナノ粒子 / シロスタゾール / 眼後部治療 / 網膜 / 緑内障 / 角膜透過 / 眼圧 / DDS / DDA |
|---|
| Outline of Final Research Achievements |
We attempted to establish a new method for preparing drug solid nanoparticles, and succeeded in preparing a high quality dispersion containing cilostazol (CLZ) nanoparticles. In addition, the instillation of the ophthalmic dispersions containing CLZ nanoparticles suppresses retinal vasoconstriction in endothelin-1-injected rats. It is possible that an ocular drug delivery system using drug nanoparticles may expand their usage as therapy in the glaucoma patient.
|
Report
(3 results)
Research Products
(6 results)
